Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir

Overview

Journal J Mol Biol

Publisher Elsevier

Specialties Microbiology
Molecular Biology

Date 2008 Jul 4

PMID 18597780

Citations 38

Authors

Fengling Liu

Andrey Y Kovalevsky

Yunfeng Tie

Arun K Ghosh

Robert W Harrison

Irene T Weber

Affiliations

Soon will be listed here.

Abstract

HIV-1 (human immunodeficiency virus type 1) protease (PR) and its mutants are important antiviral drug targets. The PR flap region is critical for binding substrates or inhibitors and catalytic activity. Hence, mutations of flap residues frequently contribute to reduced susceptibility to PR inhibitors in drug-resistant HIV. Structural and kinetic analyses were used to investigate the role of flap residues Gly48, Ile50, and Ile54 in the development of drug resistance. The crystal structures of flap mutants PR(I50V) (PR with I50V mutation), PR(I54V) (PR with I54V mutation), and PR(I54M) (PR with I54M mutation) complexed with saquinavir (SQV) as well as PR(G48V) (PR with G48V mutation), PR(I54V), and PR(I54M) complexed with darunavir (DRV) were determined at resolutions of 1.05-1.40 A. The PR mutants showed changes in flap conformation, interactions with adjacent residues, inhibitor binding, and the conformation of the 80s loop relative to the wild-type PR. The PR contacts with DRV were closer in PR(G48V)-DRV than in the wild-type PR-DRV, whereas they were longer in PR(I54M)-DRV. The relative inhibition of PR(I54V) and that of PR(I54M) were similar for SQV and DRV. PR(G48V) was about twofold less susceptible to SQV than to DRV, whereas the opposite was observed for PR(I50V). The observed inhibition was in agreement with the association of G48V and I50V with clinical resistance to SQV and DRV, respectively. This analysis of structural and kinetic effects of the mutants will assist in the development of more effective inhibitors for drug-resistant HIV.

Citing Articles

Design, Synthesis, and Biological Evaluation of Darunavir Analogs as HIV-1 Protease Inhibitors.

Ur Rehman M, Chuntakaruk H, Amphan S, Suroengrit A, Hengphasatporn K, Shigeta Y ACS Bio Med Chem Au. 2024; 4(5):242-256.

PMID: 39431267 PMC: 11487539. DOI: 10.1021/acsbiomedchemau.4c00040.

Identification of steroidal cardenolides from Calotropis procera as novel HIV-1 PR inhibitors: A molecular docking & molecular dynamics simulation study.

Swapna K, Srujana M, Mamidala E Indian J Med Res. 2024; 160(1):78-86.

PMID: 39382500 PMC: 11463882. DOI: 10.25259/IJMR_2115_23.

Prediction of protein-ligand binding affinity via deep learning models.

Wang H Brief Bioinform. 2024; 25(2).

PMID: 38446737 PMC: 10939342. DOI: 10.1093/bib/bbae081.

FMO-guided design of darunavir analogs as HIV-1 protease inhibitors.

Chuntakaruk H, Hengphasatporn K, Shigeta Y, Aonbangkhen C, Lee V, Khotavivattana T Sci Rep. 2024; 14(1):3639.

PMID: 38351065 PMC: 10864397. DOI: 10.1038/s41598-024-53940-1.

Integrative modeling of diverse protein-peptide systems using CABS-dock.

Pulawski W, Kolinski A, Kolinski M PLoS Comput Biol. 2023; 19(7):e1011275.

PMID: 37405984 PMC: 10351741. DOI: 10.1371/journal.pcbi.1011275.

References

Ghosh A, Dawson Z, Mitsuya H . Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem. 2007; 15(24):7576-80. PMC: 2112938. DOI: 10.1016/j.bmc.2007.09.010. View

Kovalevsky A, Liu F, Leshchenko S, Ghosh A, Louis J, Harrison R . Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol. 2006; 363(1):161-73. PMC: 1781337. DOI: 10.1016/j.jmb.2006.08.007. View

Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper P, Mo H . Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996; 2(7):760-6. DOI: 10.1038/nm0796-760. View

Louis J, Clore G, Gronenborn A . Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat Struct Biol. 1999; 6(9):868-75. DOI: 10.1038/12327. View

Prabu-Jeyabalan M, Nalivaika E, Romano K, Schiffer C . Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J Virol. 2006; 80(7):3607-16. PMC: 1440387. DOI: 10.1128/JVI.80.7.3607-3616.2006. View

Shafer R . Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002; 15(2):247-77. PMC: 118066. DOI: 10.1128/CMR.15.2.247-277.2002. View

Noble S, Faulds D . Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 1996; 52(1):93-112. DOI: 10.2165/00003495-199652010-00007. View

Hong L, Zhang X, Hartsuck J, Tang J . Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 2000; 9(10):1898-904. PMC: 2144469. DOI: 10.1110/ps.9.10.1898. View

Esnouf R . An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J Mol Graph Model. 1997; 15(2):132-4, 112-3. DOI: 10.1016/S1093-3263(97)00021-1. View

10.

Shafer R, Rhee S, Pillay D, Miller V, Sandstrom P, Schapiro J . HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007; 21(2):215-23. PMC: 2573394. DOI: 10.1097/QAD.0b013e328011e691. View

11.

Foulkes J, Prabu-Jeyabalan M, Cooper D, Henderson G, Harris J, Swanstrom R . Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol. 2006; 80(14):6906-16. PMC: 1489026. DOI: 10.1128/JVI.01900-05. View

12.

Wang Y, Tie Y, Boross P, Tozser J, Ghosh A, Harrison R . Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J Med Chem. 2007; 50(18):4509-15. PMC: 2751596. DOI: 10.1021/jm070482q. View

13.

. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 5):760-3. DOI: 10.1107/S0907444994003112. View

14.

Gustchina A, Weber I . Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap. FEBS Lett. 1990; 269(1):269-72. DOI: 10.1016/0014-5793(90)81171-j. View

15.

Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T . Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003; 47(10):3123-9. PMC: 201142. DOI: 10.1128/AAC.47.10.3123-3129.2003. View

16.

Munshi S, Chen Z, Yan Y, Li Y, Olsen D, Schock H . An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. Acta Crystallogr D Biol Crystallogr. 2000; 56(Pt 4):381-8. DOI: 10.1107/s0907444900000469. View

17.

Otwinowski Z, Minor W . Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26. DOI: 10.1016/S0076-6879(97)76066-X. View

18.

Kovalevsky A, Tie Y, Liu F, Boross P, Wang Y, Leshchenko S . Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem. 2006; 49(4):1379-87. PMC: 3015180. DOI: 10.1021/jm050943c. View

19.

Mahalingam B, Louis J, Hung J, Harrison R, Weber I . Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins. 2001; 43(4):455-64. DOI: 10.1002/prot.1057. View

20.

Esnouf R . Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr D Biol Crystallogr. 1999; 55(Pt 4):938-40. DOI: 10.1107/s0907444998017363. View